EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report

Dongxuan Li, Guiqin Peng

Frontiers in Pharmacology · 13.10.2026 · 17

DOI: 10.3389/fphar.2026.1951692 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.10.2026. Verfasst von Dongxuan Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-mediated hepatotoxicity (IMH) is a typical immune-related adverse event associated with the use of immune checkpoint inhibitors (ICIs), while hepatitis B virus reactivation (HBVr) is an infectious complication that may also occur during ICI therapy. However, these two conditions are usually independent and rarely co-occur in the same individual. Herein, we describe a patient with lung squamous cell carcinoma who developed HBVr and IMH simultaneously after receiving tislelizumab, and the co-existence of two episodes of HBVr brings challenges to the diagnosis and treatment of IMH. In the diagnosis of IMH, the co-existence of HBVr masked the underlying IMH, resulting in a delay in IMH treatment. In the treatment of IMH, the re-occurrence of HBVr led to a dilemma of continuing to use glucocorticoids (GCs) or stopping them. In such a clinical scenario, the multidisciplinary approach, close monitoring of liver function and HBV-DNA, and a carefully balanced treatment strategy combining GCs with intensified antiviral therapy are essential to realize the optimal management for IMH. In conclusion, medical staff should be alert to the coexistence of HBVr and IMH in patients receiving ICIs, so as to avoid missed diagnosis and treatment delay.

Schlagwörter

Stichwörter der Autor:innen

case reportglucocorticoidhepatitis B virus reactivationimmune-mediated hepatotoxicitytislelizumab

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.

Zitieren

APA

Li, D., & Peng, G. (2026). Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1951692

Vancouver

Li D, Peng G. Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1951692

BibTeX
@article{Li2026,
  author = {Li, Dongxuan and Peng, Guiqin},
  title = {Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1951692}
}
Kostenlos starten →